| 05/05 | Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromy.. | AQ |
| 04/28 | Ultomiris approved in the US for adults with generalised myasthenia gravis | AQ |
| 04/26 | BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry | AQ |
| 04/11 | PMPRB UPDATE : PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing | AQ |
| 03/31 | SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General) | AQ |
| 03/29 | PMPRB UPDATE : Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Pat.. | AQ |
| 03/18 | Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig.. | AQ |
| 03/17 | AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomir.. | AQ |
| 03/01 | AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement t.. | AQ |
| 03/01 | Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializin.. | CI |
| 02/10 | AstraZeneca sees $4B in COVID vaccine sales as revenue soars | AQ |
| 02/07 | PRIORITY NEWS : Referral To EBA Gives PCT Joint Applicants Reasons To Rejoice In 2022 | AQ |
| 01/25 | The 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada | AQ |
| 01/10 | AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to.. | AQ |
| 01/07 | AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to.. | AQ |
| 01/07 | Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurim.. | CI |
| 2021 | M&A market remains strong despite decline in activity | AQ |
| 2021 | LIFE SCIENCES : Vavilov And The New Regulatory Environment | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Exces.. | AQ |
| 2021 | Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in .. | CI |
| 2021 | OCULAR THERAPEUTIX : Announces appointment of karen-leigh edwards as senior vice president.. | AQ |
| 2021 | AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development .. | CI |
| 2021 | Alexion Pharmaceuticals, Inc. agreed to acquire remaining majority stake in Caelum Bios.. | CI |
| 2021 | ASTRAZENECA : to Mandate COVID-19 Shots for US Staff | MT |
| 2021 | ALEXION PHARMACEUTICALS : FCA Remits Pricing Decision On ALEXION'S SOLIRIS To PMPRB | AQ |
| 2021 | ASTRAZENECA : Rare Disease Drug Improves Copper Mobilization in Late-Stage Study | MT |
| 2021 | ALEXION PHARMACEUTICALS : Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotroph.. | AQ |
| 2021 | FTSE : Consumer staples, financials lift FTSE 100 after worst week since February | RE |
| 2021 | ASTRAZENECA : Unit Alexion Discontinues Late-Stage Trial of ALS Drug Candidate Due to Lack.. | MT |
| 2021 | FTSE 100 Falls as Growth Fears Persist; More Volatility Possible | DJ |
| 2021 | AstraZeneca's antibody therapy prevents COVID-19, study shows | RE |
| 2021 | Alexion Discontinues CHAMPION-ALS | CI |
| 2021 | ASTRAZENECA : Alexion to Discontinue Ultomiris Phase 3 ALS Trial | DJ |
| 2021 | ALEXION PHARMACEUTICALS : Canadian Drug Price Review Board Reined In | AQ |
| 2021 | "THIS COURT DOES NOT SIGN BLANK CHEQ : Federal Court Of Appeal Reverses Canada's Patented .. | AQ |
| 2021 | Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - executive | RE |
| 2021 | London Indexes Boosted by Positive Welcome to Most Earnings | DJ |
| 2021 | ASTRAZENECA : First-Half Revenue Soars on New Medicines, COVID-19 Vaccine Boost | MT |
| 2021 | BEN VAN BEURDEN : London Shares Rise as Miners, Oil Stocks Gain; S&N, BT Fall | DJ |
| 2021 | FTSE Edges Higher, Speculators Could Rebuild Bets on Stronger Pound | DJ |
| 2021 | AstraZeneca Lifts 2021 Guidance After Alexion Acquisition; Posts Lower 2Q Profit -- Upd.. | DJ |
| 2021 | AstraZeneca 2Q Net Profit Dropped Despite Higher Revenue; Raises Guidance | DJ |
| 2021 | ASTRAZENECA : H1 Profit Rises 42% Amid Growth In Oncology, Respiratory | MT |
| 2021 | ASTRAZENECA : EU regulator backs AstraZeneca drug for rare blood disorder in children | RE |
| 2021 | ASTRAZENECA : EU regulator endorses AstraZeneca drug for rare blood disorder in children | RE |
| 2021 | ALEXION PHARMACEUTICALS : Termination of Material Definitive Agreements (Form 8-K) | PU |
| 2021 | Alexion Pharmaceuticals, Inc. Announces Board Cessations | CI |
| 2021 | ASTRAZENECA : Closes on Acquisition of Alexion | MT |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P 500 Health Care | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P Composite 1500 | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from INDUSTRIALS | CI |
| 2021 | Alexion Pharmaceuticals, Inc.'s Equity Buyback announced on October 23, 2019, has expir.. | CI |
| 2021 | AstraZeneca PLC completed the acquisition of Alexion Pharmaceuticals, Inc.. | CI |
| 2021 | Alexion Pharmaceuticals, Inc.'s Equity Buyback announced on July 21, 2021, has expired. | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P 500 Value | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P Global 1200 | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P 500 Growth | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from FTSE All-World Index | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from NASDAQ Composite Index | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P TMI Index | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P 500 | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P 500 EQUAL WEIGHTED | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P Global BMI Index | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from S&P Biotechnology Select Industr.. | CI |
| 2021 | FTSE Bounces Back Closing Higher Despite Delta-Variant Concerns | DJ |
| 2021 | FTSE Rises, Risk Aversion Likely to Keep Pound Under Pressure | DJ |
| 2021 | Alexion Pharmaceuticals, Inc. Announces Revenue Results for the Three Months and Six Mo.. | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from NASDAQ Biotechnology Index | CI |
| 2021 | ALEXION PHARMACEUTICALS, INC.(NASDAQ : ALXN) dropped from NASDAQ-100 Index | CI |
| 2021 | Wall Street drops as Delta variant drives fears | RE |
| 2021 | CLOSE UPDATE : US Stocks Drop Friday as COVID Cases Rise, Consumer Sentiment Fades Amid St.. | MT |
| 2021 | Wall Street ends down as Delta variant drives fears | RE |
| 2021 | SECTOR UPDATE : Health Care Stocks Manage to Largely Sidestep Friday Selldown as Biotech S.. | MT |
| 2021 | Wall Street drops as Delta variant raises fears | RE |
| 2021 | Equities Slip Midday After Strong Retail Sales, Surprise Drop in Consumer Sentiment | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
